オプションチェーンは、Tempest Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Tempest Therapeuticsの市場センチメントを評価します。.

Tempest Therapeutics (NASDAQ:TPST) 株価情報, オプションチェーン

Tempest Therapeutics

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics Inc

Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:00 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BLBD

Blue Bird Q4 Earnings Assessment

The earnings results for Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) for Q4 were made public on Monday, November 25, 2024 at 04:00 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.12, resulting in a 17.0% drop change in the share price the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Q4 Earnings Assessment

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.02, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENTA

Central Garden & Pet Earnings Analysis: Q4 Recap

News

Guidance

New Jersey Resources Sees FY 2025 Adj. EPS $3.05-$3.20 Vs $2.89 Estimate

Zoom Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) reported third-quarter financial results after the market close on Monday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42174716/zoom-communications-reports-financial-results-for-the-third-quarter-of-fiscal-year-2025">key details from the quarter</a>.
Q3 Earnings: Zoom reported third-quarter revenue of $1.18 billion, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $1.16 billion. The communications company reported third-quarter adjusted earnings of $1.38&nbsp;per share, beating analyst estimates of $1.31&nbsp;per share.
Zoom has now beat analyst estimates on the top and bottom lines in nine consecutive quarters, according to data from <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 3.6% on a year-over-year basis. Enterprise revenue was up 5.8% year-over-year, while online revenue was flat year-over-year. Zoom noted online monthly average churn reached an all-time low of 2.7% in the quarter.
Net cash provided by operating activities was&nbsp;$483.2 million&nbsp;in the&nbsp;third quarter, down 2% year-over-year. Free cash flow came in at $457.7 million, up 1% year-over-year.
Zoom ended the quarter with approximately 192,400 enterprise customers; 3,995 of those customers were contributing more than $100,000 in trailing 12 months revenue at quarter&#8217;s end, up approximately 7.1% year-over-year. The company said it ended the quarter with $7.7 billion in cash, cash equivalents and marketable securities.
Zoom said its board authorized the repurchase of an additional $1.2 billion of its common stock in November, bringing the total remaining amount under the buyback to $2 billion.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42173156/crowdstrike-q3-earnings-preview-analysts-anticipate-recovery-customers-remain-confident">CrowdStrike Q3 Earnings Preview: Analysts Anticipate Recovery, &#8216;Customers Remain Confident&#8217;</a>
Guidance: Zoom expects fiscal fourth-quarter revenue to be in the range of $1.175&nbsp;billion to $1.18 billion versus estimates of $1.17 billion. The company sees fourth-quarter adjusted earnings of $1.29&nbsp;to $1.30 per share versus estimates of $1.28&nbsp;per share.&nbsp;
Zoom expects full-year revenue of $4.656&nbsp;billion to $4.661 billion versus estimates of $4.64 billion. Full-year earnings are expected to be between $5.41&nbsp;and $5.43&nbsp;per share versus estimates of $5.35 per share.
&#8220;At Zoomtopia we announced major milestones such as AI Companion 2.0 and paid add-ons for AI Companion and industry-specific AI customization, further cementing our vision to deliver a differentiated AI-first work platform that empowers customers to achieve more than ever,&#8221;&nbsp;said&nbsp;Eric Yuan, founder and CEO of Zoom.
Zoom announced that it changed its name from Zoom Video Communications to Zoom Communications on Monday. Management will further discuss the quarter on a conference call with analysts and investors&nbsp;at 5&nbsp;p.m. ET.
ZM Price Action: <a href="https://www.benzinga.com/quote/ZM" target="_blank" rel="noreferrer noopener">Zoom shares</a> were down about 2.31% after hours, trading at $86.97 at the time of publication, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/24/11/42172182/coppers-high-wire-act-can-evs-new-tech-power-the-metals-next-big-surge">Copper&#8217;s High-Wire Act: Can EVs, New Tech Power The Metal&#8217;s Next Big Surge?</a></li>
</ul>
Photo: Shutterstock.

Buybacks

Management

After-Hours Center

Movers

Zoom Communications Q3 Earnings: Revenue Beat, EPS Beat, Online Churn Hits All-Time Low, Company Name Change And More

Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:00 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Past Earnings Performance</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Blue Bird Earnings Analysis: Q4 Recap

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.38 in the last quarter, resulting in a 1.0% increase share price change the following day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Insights into Enanta Pharma Q4 Earnings

The earnings results for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) for Q4 were made public on Monday, November 25, 2024 at 04:02 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Central Garden & Pet Q4 Earnings Assessment

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:30 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
New Jersey Resources beat estimated earnings by 1.0%, reporting an EPS of $0.89 versus an estimate of $0.88.
Revenue was up $64.45 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company missed on EPS by $0.08, leading to a 2.0% increase share price change the next day.
Here's a look at New Jersey Resources's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>1.32</td>
<td>0.75</td>
<td>0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>1.41</td>
<td>0.74</td>
<td>0.30</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>283.00M</td>
<td>670.00M</td>
<td>662.00M</td>
<td>760.00M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>275.64M</td>
<td>657.91M</td>
<td>467.21M</td>
<td>331.32M</td>
</tr>
</tbody>
</table>

To track all earnings releases for New Jersey Resources <a href="https://www.benzinga.com/quote/NJR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: New Jersey Resources Q4 Earnings

Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares traded higher on Monday after the company announced a repurchase agreement for its 0% convertible senior notes due 2026. Here&#8217;s<a href="https://www.benzinga.com/quote/CHGG/news"> what you need to know.</a>
What To Know: Chegg has entered into private agreements with certain noteholders to repurchase approximately $116.6 million of its outstanding 0% convertible senior notes due 2026 for a cash price of $96.2 million. The repurchase transactions were entered into as part of Chegg's previously announced securities repurchase program.
The note repurchases are expected to close on Dec. 3. Following closing, $127.9 million aggregate principal amount of the notes will remain outstanding, while $207.5 million will remain available for repurchases under the program.
The move reduces the company's outstanding debt, which appears to have contributed to Monday&#8217;s positive market reaction. Chegg provides learning support services through its platform, offering AI-powered academic assistance and access to subject matter experts. 
Chegg reported better-than-expected financial results for the third quarter earlier this month. Multiple analysts lowered price targets following the report, ranging from $1.50 to $3 per share. 
CHGG Price Action: Chegg shares closed Monday up 12.2% at $2.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-1024x545.png" alt="" class="wp-image-664186" style="width:459px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG.png 1437w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42173927/how-rich-are-you-find-out-whether-you-rank-as-upper-middle-or-lower-class-based-on-income-and-other-factors">How Rich Are You? Find Out Whether You Rank As Upper, Middle Or Lower Class Based On Income And Other Factors</a></li>
</ul>
Photo via Shutterstock.

CHGG

Chegg Shares Rallied On Monday: What Happened?

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares closed lower on Monday. Reports indicate Tesla vehicles would not be eligible for rebates under a new California <a href="https://www.benzinga.com/news/24/07/39846836/california-ev-subsidies-made-tesla-what-it-is-but-elon-musk-is-ready-to-cut-them-off-remove-subsidie">consumer rebates proposal</a>.
What Happened: According to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-25/california-pledges-ev-buyer-rebate-if-trump-kills-7-500-credit?sref=TBDibEcD&amp;embedded-checkout=true">report</a>, California Governor Gavin Newsom outlined new plans on Monday to offer incentives for EV buyers in California if President-elect Donald Trump gets rid of the current federal $7,500 tax break for EV buyers when he returns to the White House early next year.
Newsom&#8217;s team reportedly told Bloomberg that the new proposal includes &#8220;market-share limitations&#8221; that would exclude Tesla&#8217;s EV models from tax credit eligibility.
"It's about creating the market conditions for more of these car makers to take route,"&nbsp;the governor&#8217;s office reportedly said.
Tesla CEO Elon Musk and Newsom have a &#8220;tense&#8221; relationship dating back to before Musk decided to move Tesla&#8217;s headquarters out of California. Musk pushed back against state orders to close the company&#8217;s factory during the COVID-19 pandemic, calling them &#8220;fascist.&#8221; Newsom reportedly said Tesla owed some of its success to California.
The news follows reports from earlier this month indicating that Trump's team plans to kill the $7,500 EV tax credit on vehicle purchases as part of a broader tax-reform plan.
See Also: <a href="https://www.benzinga.com/government/regulations/24/11/42160725/tesla-faces-environmental-violations-as-elon-musks-doge-prepares-for-garbage-collection-of-rules-that-dont-make-sense-report">Tesla Faces Environmental Violations As Elon Musk&#8217;s &#8216;DOGE&#8217; Prepares For &#8216;Garbage Collection Of Rules That Don&#8217;t Make Sense:&#8217; Report</a>
Musk reportedly told Trump's team that he supports <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">putting an end to the EV tax credit</a>. The Tesla CEO said earlier this year that removing the EV tax credit could have a slight impact on Tesla sales, but would be far worse for Tesla&#8217;s U.S.-based competitors. Analysts seem to agree.
Wedbush analyst&nbsp;Dan Ives&nbsp;said in a note following the news that the cuts are actually&nbsp;<a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this" target="_blank" rel="noreferrer noopener">net positive for Tesla</a>. The Wedbush analyst acknowledged that getting rid of the tax credit could weigh on demand, but he believes it will actually propel Tesla further ahead of competitors.&nbsp;
"We expect Musk to have a big seat at the table as these EV discussions happen within the Trump transition team. We believe any sell-off in Tesla from these reports is the wrong knee-jerk reaction and we would be buyers," Ives said in a recent Tesla note.
UBS analyst Joseph Spak maintained Tesla with a <a href="https://www.benzinga.com/analyst-stock-ratings">Sell rating</a> on Monday and raised the price target from&nbsp;$197&nbsp;to&nbsp;$226.
TSLA Price Action: <a href="http://benzinga.com/quote/tsla">Tesla shares</a> are up approximately 31% over the past month. The EV stock was down 3.96% at $338.59 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Tesla.

TSLA

What's Going On With Tesla Stock Today?

FLNC

Fluence Energy Expects FY25 Revenue Of Approximately $3.6B - $4.4B With Midpoint Of $4.0B (Est $3.948B)

SMARTCELLs with integrated Veea Edge Platform offer a practical solution for collection and processing of massive amounts of data for highly unique AI-driven edge applications
Visit our Booth #510 at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffall.smartcitiesconnect.org%2F&amp;esheet=54158095&amp;newsitemid=20241125091566&amp;lan=en-US&amp;anchor=Smart+Cities+Connect+Conference&amp;index=1&amp;md5=4b23dc81dbe3ae7ce6d4ca86d8452596">Smart Cities Connect Conference</a> in Austin, TX, December 3-5, 2024
MARQUEE Wireless Inc., a company specializing in integrationand deployment ofcellular, IoT andedge computing technologiesfor cellular networks and Smart Cities, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veea.com%2F&amp;esheet=54158095&amp;newsitemid=20241125091566&amp;lan=en-US&amp;anchor=Veea+Inc.&amp;index=2&amp;md5=76fd2ac704fd03a9954b41352a07faf3">Veea Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>), a pioneer in hyperconverged Multiaccess Edge Computing (MEC) with AI-driven cybersecurity and edge solutions, announced a partnership for a visionary initiative to roll out a transformative solution based on MARQUEE's patented SMARTCELL&#x2122; platform supported by Veea's Decentralized Physical Infrastructure Network (DePIN) to accelerate the introduction of MEC solutions with Edge AI as an extension of cellular network infrastructure.

VEEA

VEEA Announces A Partnership For A Visionary Initiative To Roll Out A Transformative Solution Based On  MARQUEE's Patented SMARTCELL Platform Supported By Veea's Decentralized Physical Infrastructure Network To Accelerate The Introduction Of MEC Solutions With Edge AI As An Extension Of Cellular Network Infrastructure

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.88 by 1.14 percent. The company reported quarterly sales of $395.780 million which missed the analyst consensus estimate of $407.000 million by 2.76 percent. This is a 19.45 percent increase over sales of $331.325 million the same period last year.

Earnings Beats

Earnings Misses

New Jersey Resources Q4 2024 Adj. EPS $0.89 Beats $0.88 Estimate, Sales $395.780M Miss $407.000M Estimate

Dana Announces Plan To Sell Off-Highway Business; Co. Also Initiates Cost Reduction Plan, Expecting To Deliver Annualized Savings Of ~$200M By 2026, Says Plans To Reduce Capital Spending To Reflect The Revised Market Demand For Electric Vehicles

<ul>
<li>Ashley Buchanan Appointed Chief Executive Officer and Board Member, Starting January 15</li>
<li>Tom Kingsbury Plans to Step Down as CEO on January 15, Retaining an Executive Advisory Role and Board Seat Through His Retirement in May 2025</li>
</ul>
Kohl's Corporation ("Kohl's" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) today announced that Chief Executive Officer Tom Kingsbury plans to step down as CEO, effective January 15, 2025. He will stay on in an advisory role to the new CEO and retain his position on Kohl's Board of Directors (the "Board") through his retirement in May 2025, after which the size of the board will be reduced by one.
The Board has appointed retail veteran Ashley Buchanan as CEO, effective January 15. Buchanan has been CEO of Michaels Companies since 2020 and, prior to that, has held a variety of senior executive roles at Walmart and Sam's Club during his 13 years at the company.

Kohl's Announces CEO Transition Process; Ashley Buchanan Appointed CEO And Board Member, Starting January 15; Tom Kingsbury Plans To Step Down As CEO On January 15, Retaining An Executive Advisory Role And Board Seat Through His Retirement In May 2025

Dana Appoints Current Director R. Bruce McDonald As Chairman And CEO

Universal Health Realty Income Trust (NYSE:&nbsp;UHT) announced today that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.735 per share on December 31, 2024 to shareholders of record as of December 16, 2024.

Dividends

Universal Health Realty Income Trust Announces Dividend Increase From $0.73 To $0.735 Per Share

Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
In the previous quarter, the company beat on EPS by $0.4, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Blue Bird Earnings Review: Q4 Summary

Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Earnings Report: Q4 Overview

Roche collaboration for lead asset boosts Tempest

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Tempest Therapeutics (TPST – Research Report). The associated price...

Buy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche Collaboration

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price ta...

Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Allakos (ALLK – Research...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)

Pre-earnings options volume in Tempest Therpeutics is normal with calls leading puts 22:1. Implied volatility suggests the market is anticipating a...

Tempest Therpeutics options imply 22.5% move in share price post-earnings

Tempest Therapeutics (TPST) announced that the company received a "Study May Proceed" letter from the U.S. Food and Drug Administration, FDA, to ev...

Tempest receives FDA study may proceed for Phase 3 trial of amezalpat

Tempest Therapeutics GAAP EPS of -$0.41 misses by $0.05

"During the third quarter, the team continued to move amezalpat successfully towards the pivotal study, achieving important milestones on both the ...

Tempest Therapeutics reports Q3 EPS (41c), consensus (36c)

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantgini...

Tempest Therapeutics: Promising Advancements and Strategic Partnerships Justify Buy Rating

Tempest Therapeutics, Inc. ( ($TPST) ) has released its Q3 earnings. Here is a breakdown of the information Tempest Therapeutics, Inc. presented to...

Tempest Therapeutics Reports Q3 2024 Financial Results

ALLK

ALNY

RHHBF

RHHBY

TPST

Press Releases

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Health Care

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Extends Limited Duration Stockholder Rights Plan

Contracts

General

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Comments

Tempest Therapeutics

Tempest Therapeutics (TPST) オプション

Tempest Therapeutics (NASDAQ:TPST) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル